[IDXX] IDEXX: Q3 2026 Earnings Test Diagnostics Growth as Vet Visits Fall

IDEXX Laboratories (IDXX) is an animal diagnostics company headquartered in Westbrook, Maine, and its companion animal business, which sells in-clinic analyzers and consumables, SNAP rapid tests and outside reference laboratory services to veterinary practices, generated 92% of 2025 revenue[1][2]. According to the Drillr earnings calendar, IDEXX Q3 2026 earnings are scheduled for 2026-11-02, covering the Third quarter 2026 (three months ended September 30, 2026)[3]. The latest reported quarter is the second quarter of 2026: revenue was $1.2166 billion, up 9.7% year over year (9% organic), companion animal diagnostics recurring revenue grew 10.3% organically, gross margin was 64.0%, operating margin was 35.0% and free cash flow was $322.5 million[4][2][5]. On August 4 the company narrowed full-year revenue guidance to $4.700 billion to $4.745 billion with 8.5%–9.7% organic growth, raised EPS guidance to $14.69–$14.94 and set operating margin guidance at 32.3%–32.5%; on the call, management said third-quarter organic growth would align with the implied second-half range, with a foreign exchange headwind of about 0.7 percentage points to reported revenue and 20–50 basis points of comparable operating margin expansion[2][5]. The Drillr consensus of 8 analysts for the third quarter is revenue of about $1.1913 billion and EPS of $3.72[6].

Three things matter most in this report. The first is whether companion animal diagnostics recurring revenue can keep growing about 10% organically while U.S. clinical visits keep falling by about 1.5%: this line was $974.7 million in the second quarter, roughly 80% of company revenue, and grew 10.7% organically in the first half, so its path shows whether growth comes from more testing per visit or mainly from price[4][5]. The second is the pace of inVue Dx cell morphology analyzer placements: IDEXX placed about 2,700 units in the first half and needs about 1,400 in the third quarter to reach its 5,500-unit full-year target, and whether the new installed base keeps VetLab consumables growing about 13% or more organically determines the consumable revenue these instruments generate for years[5][2]. The third is margin after the stepped-up second-half R&D and commercial investment: management guided third-quarter comparable operating margin expansion of only 20–50 basis points, below the 110 basis points delivered in the second quarter, and the report will show whether gross margin gains can cover expense growth and keep converting into cash[5][2].

Company Background and Business Structure

IDEXX is built around diagnostics: it develops, manufactures and sells diagnostic products and services for companion animal veterinarians, livestock, poultry and dairy producers, and water testing, with companion animal diagnostics at the core[1]. In the clinic it offers the Catalyst chemistry analyzer, premium hematology analyzers, the SediVue urine sediment analyzer and the inVue Dx cell morphology analyzer that reached broad commercial availability in the second quarter of 2025, alongside SNAP rapid assay tests, a global reference laboratory network, practice management software and digital imaging systems[4]. The chief executive is Jay Mazelsky[7].

IDEXX reports three segments plus an Other business, and the Companion Animal Group (CAG) dominates[1]. CAG revenue was $3.953 billion in 2025, including $3.407 billion of diagnostics recurring revenue (VetLab consumables $1.497 billion, rapid assays $349 million, reference laboratory diagnostic and consulting services $1.424 billion, and diagnostics services and accessories $137 million), $200 million of diagnostic instrument revenue and $346 million from veterinary software, services and diagnostic imaging systems[1]. The Water segment, which supplies tests and instruments for detecting microbiological parameters in water, had 2025 revenue of $201 million; Livestock, Poultry and Dairy had $132 million; and Other, mainly human medical diagnostics and out-licensing, had $17 million[1][4].

CAG customers are veterinary practices and corporate hospital groups, and many instruments are placed in exchange for multi-year commitments to buy consumables, after which practices keep buying consumables and lab services in line with test volumes[1]. Instruments are sold once, while consumables, rapid tests, lab services and maintenance are recurring and carry much higher gross margins than instrument sales, so each quarter's revenue mix directly moves gross margin[1]. In 2025, U.S. revenue was $2.753 billion and international revenue $1.551 billion, about 36% of the total; the international companion animal business grew 12.0% organically, faster than 8.7% in the U.S.[1]. IDEXX has no material consolidation or equity-method arrangements, and its only such item in the first half of 2026 was a $5 million loss on an equity investment recorded in operating expenses[2].

Financial History and Current Position

2025 was a year of higher revenue and higher margins together[1]. Full-year revenue was $4.304 billion, up 10.4% from $3.898 billion in 2024 and 9.6% organically; operating income was $1.360 billion, operating margin rose from 29.0% in 2024 to 31.6%, gross margin rose from 61.0% to 61.8%, and net income was about $1.059 billion[1]. In the same year CAG diagnostics recurring revenue grew 8.1% organically, reference laboratories grew 5.9% organically, and diagnostic instrument revenue grew 49.3% organically on the inVue Dx launch[1].

Cash generation in 2025 roughly matched profit[1]. Operating cash flow was $1.182 billion, capital expenditure was about $125 million, free cash flow was roughly equal to net income, and net debt was $670 million at year-end[1].

Growth and margins in the first half of 2026 both ran ahead of the prior year[4]. First-half revenue was about $2.357 billion, up from $2.108 billion in the first half of 2025; operating income was $788.2 million and operating margin was 33.4%, 70 basis points higher than a year earlier[4][2]. First-half operating cash flow was $613.4 million and free cash flow $556.8 million, up from $423.7 million and $359.6 million, partly because the prior-year period included a litigation settlement payment of about $80 million[2][4].

The second quarter is the latest official data point[4]. Revenue was $1.2166 billion, up 9.7% (9% organic), gross margin was 64.0%, operating income was $425.6 million for a 35.0% margin, and free cash flow was $322.5 million[4][2]. Cash went mainly to buybacks: IDEXX repurchased $351 million of stock in the first quarter and $332 million in the second, borrowed a net $121 million under its credit facility in the first half, and cut diluted shares outstanding by about 2% year over year[8][5][4].

Operating Model

Company revenue is driven almost entirely by CAG, and CAG diagnostics recurring revenue can be broken into three factors: clinical visits, testing frequency and menu per visit, and realized price[1][5]. By channel, VetLab consumables roughly equal the active premium installed base times tests per instrument times consumable price, SNAP rapid tests roughly equal tests ordered during visits times kit price, and reference laboratories roughly equal sent-out test volume times the fee per test[1]. These three lines move in the same period as visits and testing behavior change, while the consumable contribution from instrument placements builds over the years after installation. Full-year 2026 revenue guidance is $4.700–$4.745 billion, including 9.5%–10.7% organic growth in CAG diagnostics recurring revenue, and management assumes about 4% global net price realization[2][5].

Instrument revenue is recognized once and is often exchanged for multi-year consumable commitments, so a heavy placement quarter lifts instrument revenue and lowers gross margin in that quarter while laying the base for later consumable growth[1]. In the second quarter of 2026, diagnostic instrument revenue fell 20% organically against the high base of the broad inVue Dx launch in the same quarter of 2025, even though IDEXX still placed 5,265 premium instruments in the quarter[2][5].

Gross profit combines high-margin recurring revenue with lower-margin instrument and system revenue, minus inflationary costs and plus net price and productivity, so the higher the instrument share in a quarter, the lower the gross margin[1][4]. Operating income is gross profit minus sales and marketing (14.1% of revenue in the second quarter), general and administrative (9.6%) and R&D (5.4%) expenses, which produced a 35.0% operating margin in the second quarter[4]. Management's full-year operating margin guidance of 32.3%–32.5% and third-quarter comparable operating margin expansion of 20–50 basis points reflect incremental second-half R&D and commercial investment that will weigh on margins in the period, with the spending aimed at long-term growth[2][5].

Cash flow follows the steady purchase of consumables and testing services and is seasonal: first-quarter operating cash flow is lower because the prior year's employee bonuses are paid then, and the remaining quarters are higher[8][4]. IDEXX plans capital expenditure of about $180 million in 2026, guides full-year free cash flow conversion at 90%–100% of net income, and reported trailing 12-month conversion of about 110% through June 2026[4][5][2]. Free cash flow goes mainly to share repurchases, supplemented by borrowing under the revolving credit facility[4].

Industry and Competitive Position

IDEXX competes in both point-of-care testing inside the clinic and outside reference laboratory testing[1]. Its main North American competitors are Mars brands Antech Diagnostics and Heska, and Zoetis (including Abaxis); internationally it also faces Fujifilm, Arkray, Mindray and BioNote, among others[1]. Some corporate hospital chains run their own reference labs, such as Mars-owned VCA, which serves both its own and unaffiliated hospitals[1].

Sector growth currently comes from more testing per visit, not from visit volume[1]. In 2025, U.S. same-store practice diagnostics revenue grew about 6%, faster than about 2% growth in overall practice revenue, while same-store clinical visits fell about 2%; visits fell about 1% in the first quarter of 2026 and about 1.5% in the second[1][7][5]. Management attributes the decline in wellness visits to consumer pressure from higher housing and energy costs and to the post-pandemic drop in puppy adoptions, while noting that both wellness and non-wellness visits are growing for pets aged five and older[5].

IDEXX's advantages show up mainly in installed base scale, customer retention and new test menu[1][5]. At the end of 2025 the installed base was about 78,000 Catalyst units, 56,000 premium hematology analyzers, 24,000 SediVue units and 6,000 inVue Dx units; by June 30, 2026 the premium installed base was up 11% year over year, and CAG diagnostics customer retention was holding in the high 90% range[1][5]. About 20% of CancerDx orders in the second quarter came from clinics using competing reference labs, a sign that new tests are bringing in new customers[5].

The available comparisons have clear limits[1]. U.S. visit data come from a sample of IDEXX customers, which the company itself describes as limited and susceptible to short-term swings, and there are no visit data for international markets; the materials also contain no competitor growth rates on the same basis, so "outpacing the sector" can only be judged on the company's own measure[1][2].

Core Debates

Can diagnostics revenue keep growing about 10% while vet visits shrink?

This debate determines the quality of IDEXX's growth, because CAG diagnostics recurring revenue is roughly 80% of company revenue and the main source of profit and cash[4]. U.S. same-store clinical visits fell about 2% in 2025 and management expects a decline of about 1.5% in the second half of 2026, yet this revenue line grew 10.7% organically in the first half[1][5][4]. If growth comes mainly from more testing per visit and new tests, falling visits matter little; if it relies more on price, growth becomes more fragile as visits keep declining.

Second-quarter evidence leans toward volume-driven growth, but price also contributed meaningfully[4]. CAG diagnostics recurring revenue was $974.7 million, up 10.3% organically (11.0% reported), with about 10% in the U.S. and about 12% internationally; reference laboratory revenue was $406.7 million, up 10.3% organically, VetLab consumables grew 13.6% organically, and SNAP rapid assay revenue was $101.6 million, up 1.1% organically[4][5]. The company attributed growth to higher testing volumes, new customers and higher realized prices, and raised full-year guidance to 9.5%–10.7% organic growth, including about 4% net price[4][2][5]. For comparison, reference laboratories grew only 5.9% organically for full-year 2025 and 10.0% in the first half of 2026[1][4].

The financial transmission multiplies clinical visits, testing frequency and new tests per visit (CancerDx, SDMA added to routine panels and similar additions) and net price to set reference lab volume and VetLab consumable and SNAP kit sales, which sum to CAG diagnostics recurring revenue and company gross profit[1][5]. What remains unresolved is how much growth reflects a change in veterinarian behavior: an alternative explanation is that the visit mix is shifting toward older pets and non-wellness visits that already require more testing, so part of the growth comes from case mix; if wellness visits keep falling, reference lab gains would slow first[5]. The company gives only a full-year net price assumption and does not disclose a quarterly volume-price split, which leaves the judgment dependent on indirect signals.

In the third quarter, watch whether CAG diagnostics recurring revenue grows at least 10% organically, or at minimum holds the implied second-half floor of about 8.3%; whether reference labs stay around 10% and rapid assays keep growing; and whether the U.S. visit decline stays within about 1.5% without a wider drop in wellness visits. The observable falsifiers are these: if the U.S. visit decline widens beyond 2.5%, reference labs and rapid assays would feel it first; if the roughly 4% net price has to be bought with customer discounts, recurring growth would lean more on volume and the view that testing frequency offsets falling visits would weaken.

Can inVue Dx reach 5,500 placements this year and turn them into consumable revenue?

This debate concerns whether instrument placements turn into years of consumable revenue, because IDEXX sells each instrument once and the long-term value comes from consumable purchases afterward[1]. The inVue Dx cell morphology analyzer is IDEXX's most important new instrument in recent years; it reached broad availability in the second quarter of 2025 and its cumulative placements passed 9,000 by the second quarter of 2026[4][2]. The third quarter is the first checkpoint for second-half placements: a shortfall would push the full-year target into the fourth quarter, while consumable growth shows whether practices are actually using the new instruments heavily.

First-half placement pacing broadly matched the target[5]. Premium instrument placements were 5,265 in the second quarter, including 1,602 inVue Dx units, compared with 4,650 and about 1,100 in the first quarter; first-half inVue Dx placements were about 2,700, and management said it was confident of reaching 5,500[5][7][9]. The global premium installed base grew 11% year over year, second-quarter VetLab consumables revenue was $430.3 million, up 13.6% organically (14.5% in the first half), and consumable revenue per inVue instrument was within the previously guided range of $3,500–$5,500[4][5]. The fine needle aspirate (FNA) application is in a controlled launch, with broad availability planned by the end of 2026[5].

The financial transmission runs from the sales team trading consumable commitments for placements, to installed base times tests per instrument times consumable price, which forms VetLab consumables revenue; instrument revenue is recognized once and dilutes gross margin in heavy placement quarters[1][4]. What remains unresolved is how much consumable growth reflects genuinely higher utilization: an alternative explanation is that first-half placements partly benefited from favorable terms tied to multi-year consumable commitments and that consumable growth includes a net price contribution; if the broad FNA launch slips, utilization gains on the new installed base would come more slowly than planned[2][5].

In the third quarter, watch whether inVue Dx placements reach about 1,400 and the company reaffirms 5,500 for the year, whether total premium placements stay at or above the first quarter's 4,650 with installed base growth holding at 11%, and whether VetLab consumables keep growing about 13% organically rather than slipping toward installed base growth. The falsifying signals are these: if third-quarter inVue Dx placements fall below 1,100, the full-year target would depend on a record fourth quarter; if consumable growth approaches installed base growth, tests per new instrument are not rising.

Can margins keep expanding as IDEXX steps up second-half investment?

This debate tests whether margin expansion can continue after the added investment[2]. IDEXX's operating margin was 33.4% in the first half of 2026 and reached 35.0% in the second quarter, driven mainly by growth in high-margin consumables and reference labs, productivity and pricing[2][4]. Management plans incremental R&D and commercial investment in the second half and guided third-quarter comparable operating margin expansion of only 20–50 basis points, below 110 basis points in the second quarter[5][2].

Second-quarter margin expansion came mainly from gross margin[2]. Gross margin was 64.0%, up 140 basis points year over year and 120 basis points on a comparable basis, which the company attributed to consumable and reference lab volume growth, a lower instrument revenue share, productivity and net price[2][4]. Operating expenses were $353.5 million, or 29.1% of revenue, up 10% reported and 9% comparable; operating margin was 35.0%, up 140 basis points reported and 110 basis points comparable[2][4]. First-half free cash flow was $556.8 million, about 90% of net income, and the company raised full-year operating margin guidance to 32.3%–32.5% and free cash flow conversion guidance to 90%–100%[2][5].

Full-year guidance implies a second-half operating margin of about 31.2%–31.6%, still above about 30.5% in the second half of 2025; gross margin was about 61.1% in the second half of 2025 and about 61.8% for the full year[2][1][4]. The financial transmission runs from a higher recurring revenue share, productivity and net price lifting gross margin, minus the stepped-up second-half sales, R&D and IT investment, to operating margin, and then through net income to free cash flow and buybacks[4][5]. What remains unresolved is how much of second-quarter gross margin came from mix: an alternative explanation is that the sharp year-over-year drop in instrument revenue supplied part of the gain, the third quarter still laps the 2025 inVue launch peak, and if placements later rebound, gross margin expansion would narrow naturally without implying operating deterioration[4].

In the third quarter, watch whether comparable operating margin expansion lands within 20–50 basis points with the full-year 32.3%–32.5% guidance intact, whether comparable gross margin expansion stays around 100 basis points with comparable expense growth held within 11%, and whether nine-month free cash flow conversion stays at or above 90% with buybacks continuing. The falsifiers are these: if comparable expense growth exceeds 13%, third-quarter operating margin could fall year over year; if a placement rebound pulls gross margin down, mix effects must first be separated from price and productivity before concluding that margin expansion has truly stopped.

Risks and Falsifiers

Currency is the most direct disturbance to reported figures, because about 36% of revenue comes from outside the United States[1]. Management estimates that each 1% strengthening of the U.S. dollar reduces full-year revenue by about $8 million and EPS by about $0.03, and it expects currency to cut third-quarter reported revenue growth by about 0.7 percentage points[5]. If the gap between reported and organic growth in the third quarter is no more than 0.7 percentage points and full-year EPS guidance holds, this risk has not exceeded the range the company has already given.

Competitive risk is concentrated in reference laboratories[1]. Mars brands Antech and Heska and Zoetis compete in both in-clinic instruments and reference labs, and labs run by corporate hospital chains can keep test volume inside their own networks; reference labs generated $1.424 billion in 2025, about one third of company revenue, so each 1 percentage point of slower growth costs about $14 million of annual revenue[1]. If third-quarter reference lab organic growth is at least 8% and the company keeps reporting net customer gains, the view that IDEXX is gaining share still holds.

Visit decline risk falls directly on CAG diagnostics recurring revenue, because pet owners cutting wellness visits would first reduce reference lab and rapid assay volumes[5]. Guidance implies second-half revenue for this line of about $1.856–$1.897 billion; on the second-half 2025 base of $1.723 billion, each 1 percentage point of slower organic growth costs about $17 million of second-half revenue[2][1][4]. If the third-quarter U.S. visit decline is no more than 1.5% and CAG diagnostics recurring revenue grows at least 10% organically, this risk has not materialized.

Placement and utilization risk would show up first in VetLab consumables, since practices could delay instrument decisions as visits fall or newly placed inVue Dx units could be used less than planned[5]. Using the $3,500–$5,500 range of annual consumable revenue per inVue instrument, 1,000 fewer placements would mean about $3.5–$5.5 million less annual consumable revenue; on the second-quarter base of $430.3 million, each 1 percentage point of slower VetLab consumables organic growth costs about $4.3 million of quarterly revenue[5][4]. If third-quarter inVue Dx placements are at least 1,400 and VetLab consumables grow at least 13% organically, this risk does not hold.

Investment and margin risk lies in second-half R&D and commercial spending outpacing gross profit growth and halting operating margin expansion[5]. On full-year revenue of about $4.7 billion, each 10 basis points of lower full-year operating margin costs about $4.7 million of operating income; on the second-quarter operating expense base of $353.5 million, each 1 percentage point of faster expense growth adds about $3.5 million of cost[2][4]. If third-quarter comparable operating margin expansion is at least 20 basis points and full-year guidance holds, margin expansion is still intact.

What to Watch Next

• Diagnostics growth as visits fall: CAG diagnostics recurring revenue grew 10.3% organically in the second quarter of 2026 ($974.7 million) and 10.7% in the first half; at least 10% in the third quarter confirms the view, while a drop below the implied second-half floor of about 8.3% weakens it.
• U.S. same-store clinical visits: about −1.5% in the second quarter and about −1% in the first; a decline of no more than 1.5% confirms, while a decline wider than 2.5% falsifies.
• Reference labs and rapid assays: 10.3% and 1.1% organic growth in the second quarter; reference labs near 10% with positive rapid assay growth confirms, while reference labs below 8% weakens the view.
• inVue Dx placements: 1,602 in the second quarter and about 2,700 in the first half; about 1,400 with a reaffirmed 5,500 target confirms, while fewer than 1,100 weakens.
• Premium placements and installed base: 5,265 placements in the second quarter with the installed base up 11%; placements of at least 4,650 with installed base growth holding at 11% confirms.
• VetLab consumables: 13.6% organic growth in the second quarter ($430.3 million); about 13% confirms, while growth close to installed base growth falsifies.
• Comparable operating margin: +110 basis points in the second quarter against third-quarter guidance of +20–50 basis points; at least 20 basis points with the 32.3%–32.5% full-year range intact confirms.
• Comparable gross margin and expenses: gross margin +120 basis points and expenses +9% in the second quarter; about +100 basis points of gross margin with expense growth no higher than 11% confirms, while expense growth above 13% weakens.
• Free cash flow conversion: about 90% in the first half against 90%–100% full-year guidance; nine-month conversion of at least 90% confirms.

Conclusion

IDEXX's business is driven by two relationships: how much testing practices do per visit, and how much consumable revenue newly placed instruments generate[1]. Its financial position is strong, with second-quarter 2026 revenue of $1.2166 billion, a 35.0% operating margin and first-half free cash flow of $556.8 million, returned to shareholders through buybacks funded partly with modest borrowing[4][2]. The central unresolved relationship is how much of roughly 10% diagnostics recurring revenue growth comes from testing frequency and new tests versus about 4% net price while U.S. visits fall about 1.5%, and whether margins can keep expanding after the second-half investment step-up[5].

Between the August 4, 2026 second-quarter release and October 30, the coverage found consisted mostly of results and investor day reports, product launches, deal announcements and broker adjustments to share-price views, none of which is independent analysis that can be checked against these debates, so no outside view is cited here. The only reference points readers have are company guidance and the Drillr compilation for the third quarter (revenue of about $1.1913 billion and EPS of $3.72), and those figures by themselves do not show how the market sees the three debates[6].

The combination that would materially strengthen the current understanding is third-quarter CAG diagnostics recurring organic growth of at least 10% with the U.S. visit decline within 1.5%, inVue Dx placements of about 1,400 with VetLab consumables still growing about 13% organically, and comparable operating margin expansion within 20–50 basis points with full-year guidance intact. Conversely, if the visit decline widens beyond 2.5%, reference lab growth falls below 8%, inVue Dx placements come in under 1,100 and comparable expense growth tops 13%, the first-half pattern of volume-driven growth with expanding margins could no longer be treated as durable.

Sources

[1] IDXX FY2025 10-K filed 2026-02-20 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/874716/000087471626000038/

[2] IDXX Q2 2026 8-K filed 2026-08-04 · 2026-08-04 · 8-K · https://www.businesswire.com/news/home/20260802055382/en/IDEXX-Laboratories-Announces-Second-Quarter-Results/

[3] IDXX earnings calendar updated 2026-10-29 · 2026-10-29 · Drillr earnings calendar

[4] IDXX Q2 2026 10-Q filed 2026-08-04 · 2026-08-04 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000874716&type=10-Q

[5] IDXX Q2 2026 earnings call 2026-08-04 · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[6] Drillr analyst estimates IDXX Q3 2026 retrieved 2026-10-29 · 2026-10-29 · Drillr analyst estimates · https://gateway.drillr.ai/mcp/private

[7] IDXX Q1 2026 earnings call 2026-05-05 · 2026-05-05 · earnings-call · https://gateway.drillr.ai/mcp/private

[8] IDXX Q1 2026 10-Q filed 2026-05-05 · 2026-05-05 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000874716&type=10-Q

[9] IDXX Q1 2026 8-K filed 2026-05-05 · 2026-05-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000874716&type=8-K